BTIG analyst Mark Palmer downgrades Paya Holdings (NASDAQ:PAYA) from Buy to Neutral.
Medtronic Announced Symplicity HTN-3 Trial Data Show Sustained Long-term Blood Pressure Reductions With Medtronic Renal Denervation Procedure
Medtronic plc (NYSE: MDT) today announced long-term results from the SYMPLICITY HTN-3 clinical trial.